Lead Product(s) : Pindolol
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.
Product Name : ACM-001
Product Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2021
Lead Product(s) : Pindolol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Actimed Therapeutics Successfully Closed of £2.5m Extended Seed B Funding Round
Details : The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.
Product Name : ACM-001
Product Type : Small molecule
Upfront Cash : Undisclosed
June 10, 2021
Reset All
